Abstract
Abstract: :
Purpose:To compare CNV lesion characteristics identified on fluorescein angiography (FA) with those found on ICG in patients with occult with no classic CNV. Methods:The Visudyne in Occult (VIO) Trial is a Phase 3, multicenter, double–masked randomized trial designed to determine if photodynamic therapy with verteporfin can reduce the risk of vision loss in AMD patients with subfoveal occult with no classic CNV confirmed on fluorescein angiography prior to randomization. ICG angiography could be obtained optionally at baseline and was performed in 191 of the total 364 enrolled study participants. Both ICG and FA were graded for various lesion parameters at separate times, without knowledge of treatment assignment, at an independent Reading center. Results:All patients had occult CNV with no classic CNV on fluorescein angiography, with CNV area measuring at least 50% of total lesion area. Mean total lesion area with FA was 3.19 disc areas, with mean GLD of 3696um. On ICG, 40% (76/191) had a plaque with no hot spots, 7% had a plaque with hot spots, 36% had hot spots with no plaque, and 17% had neither a plaque or hot spot. With ICG, the mean total lesion area measures 1.43 disc areas, with GLD of 1958 um.. Those lesions with a plaque graded as present on ICG (90/191) have an area that more closely approximates total lesion area on FA with a mean of 3.14 disc areas. 46% of hot spots are located within 500 um of the center. ICG identified 51 lesions (26.8%) with feeder vessels. Only 3 patients had a polypoidal lesion. Conclusions:The VIO Trial provides an opportunity to compare FA and ICG features of occult CNV with no classic lesions in a large number of patients. Plaques and hot spots were the most commonly associated features on ICG., Correlations between FA and ICG features are planned. Furthermore, visual acuity outcomes by baseline ICG features will be explored.
Keywords: age–related macular degeneration • clinical (human) or epidemiologic studies: treatment/prevention assessment/controlled clinical trials • photodynamic therapy